Aravive, Inc. Contracts & Agreements

General Assignment for the Benefit of Creditors, dated January 17, 2024, by and between Aravive, Inc. and Aravive (assignment for the benefit of creditors), LLC (Filed With SEC on January 17, 2024)

Separation Agreement and Release by and between Gail McIntyre, Ph.D. and Aravive, Inc., dated January 17, 2024 (Filed With SEC on January 17, 2024)

Separation Agreement and Release by and between Rudy C. Howard and Aravive, Inc., dated January 17, 2024 (Filed With SEC on January 17, 2024)

Offer Letter, dated April 10, 2023, by and between Aravive, Inc. and Maria Carolina Petrini (Filed With SEC on April 11, 2023)

Inducement Stock Option Grant Notice and Aravive, Inc. Inducement Stock Option Agreement, dated April 10, 2023, by and between Aravive, Inc. and Maria Carolina Petrini (Filed With SEC on April 11, 2023)

Description of Capital Securities (Filed With SEC on March 15, 2023)

Amendment No. 3 to Offer Letter dated as of February 1, 2023 by and between Aravive, Inc. and Gail McIntyre, Ph.D (Filed With SEC on February 6, 2023)

Amendment No. 1 to Offer Letter dated as of February 1, 2023 by and between Aravive, Inc. and RudyHoward (Filed With SEC on February 6, 2023)

Amendment No. 1 to Offer Letter dated as of February 1, 2023 by and between Aravive, Inc. and Robert Geller, M.D (Filed With SEC on February 6, 2023)

Amendment No. 1 to Offer Letter dated as of February 1, 2023 by and between Aravive, Inc. and Leonard Scott Dove, Ph.D (Filed With SEC on February 6, 2023)

Form of Securities Purchase Agreement, dated October 24, 2022, by and among Aravive, Inc. and the purchasers party thereto (Filed With SEC on October 28, 2022)

Form of Pre-Funded Warrant (Filed With SEC on October 26, 2022)

Form of Series A Warrant (Filed With SEC on October 26, 2022)

Form of Series B Warrant (Filed With SEC on October 26, 2022)

Form of Securities Purchase Agreement, dated October 24, 2022, by and among Aravive, Inc. and the purchasers party thereto (Filed With SEC on October 26, 2022)

Form of Side Letter Agreement by and among Aravive, Inc. and the persons party thereto (Filed With SEC on October 26, 2022)

Form of Side Letter Agreement by and among Aravive, Inc. and the BVF Investor party thereto (Filed With SEC on October 26, 2022)

Form of Registration Rights Agreement by and among Aravive, Inc. and the persons party thereto (Filed With SEC on October 26, 2022)

Form of Affiliate Registration Rights Agreement, by and among Aravive, Inc. and the persons party thereto (Filed With SEC on October 26, 2022)

Offer Letter, dated June 13, 2022, by and between Aravive, Inc. and Dr. Robert B. Geller (Filed With SEC on July 5, 2022)

Offer Letter, dated June 2, 2022, by and between Aravive, Inc. and Rudy C. Howard (Filed With SEC on June 3, 2022)

Consulting Agreement, dated June 2, 2022, by and between Aravive, Inc. and Vinay Shah (Filed With SEC on June 3, 2022)

Separation Agreement and Release, dated June 2, 2022, by and between Aravive, Inc. and Vinay Shah (Filed With SEC on June 3, 2022)

Form of Investor Warrant (Filed With SEC on March 31, 2022)

Form of Eshelman Warrant (Filed With SEC on March 31, 2022)

Form of Pre-Funded Warrant (Filed With SEC on March 31, 2022)

Form of Securities Purchase Agreement, dated March 29, 2022 by and between Aravive, Inc. and the purchaser party thereto (Filed With SEC on March 31, 2022)

Form of Securities Purchase Agreement, dated March 29, 2022 by and between Aravive, Inc. and Eshelman Ventures, LLC (Filed With SEC on March 31, 2022)

Offer Letter between Leonard Scott Dove, Ph.D. and Aravive, Inc (Filed With SEC on March 22, 2022)

Form of Pre-Funded Common Stock Purchase Warrant of Aravive, Inc (Filed With SEC on January 4, 2022)

Investment Agreement, dated as of January 3, 2022, by and among Aravive, Inc., Eshelman Ventures, LLC, and solely for purposes of Article IV and V of the Investment Agreement,... (Filed With SEC on January 4, 2022)

Sublease Agreement by and between Aravive, Inc. and Grail, Inc (Filed With SEC on June 14, 2021)

Description of Capital Securities (Filed With SEC on March 16, 2021)

Offer Letter, dated September 8, 2020 between Reshma Rangwala and the Company (Filed With SEC on March 16, 2021)

Securities Purchase Agreement, dated February 12, 2021, by and between Aravive, Inc. and Eshelman Ventures, LLC (Filed With SEC on February 16, 2021)

Amendment to Offer Letter dated as of January 25, 2021 by and between Aravive, Inc. and Gail McIntyre, Ph.D (Filed With SEC on January 27, 2021)

Consulting Agreement, dated December 31, 2020, between the Company and Ray Tabibiazar (Filed With SEC on January 4, 2021)

Collaboration and License Agreement between Aravive, Inc. and 3D Medicines Inc. dated November 6, 2020 (Filed With SEC on November 10, 2020)

Investment Agreement, dated as of April 6, 2020, by and among the Company, Eshelman Ventures, LLC, and, solely for purposes of Article IV and Article V of the Investment... (Filed With SEC on April 9, 2020)

Separation Agreement dated April 8, 2020 between the Company and Rekha Hemrajani (Filed With SEC on April 9, 2020)

Option Agreement dated April 8, 2020 by and between the Company and Srini Akkaraju (Filed With SEC on April 9, 2020)

Option Agreement dated April 8, 2020 by and between the Company and Jay Shepard (Filed With SEC on April 9, 2020)

Option Agreement dated April 8, 2020 by and between the Company and Robert Hoffman (Filed With SEC on April 9, 2020)

Amendment to Offer Letter dated as of April 8, 2020 by and between the Company and Gail McIntyre (Filed With SEC on April 9, 2020)

Description of Capital Securities (Filed With SEC on March 27, 2020)

Offer Letter, dated March 26, 2020, between Vinay Shah and Aravive, Inc (Filed With SEC on March 27, 2020)

Offer Letter, dated March 26, 2020 between Gail McIntyre and Aravive, Inc (Filed With SEC on March 27, 2020)

Form of 2019 Equity Incentive Plan Restricted Stock Unit Grant Notice and Restricted Stock Unit Award Agreement (Filed With SEC on March 27, 2020)

Offer Letter, dated January 8, 2020, between Rekha Hemrajani and Aravive, Inc (Filed With SEC on January 9, 2020)

Separation Agreement, dated January 9, 2020, between Jay Shepard and Aravive, Inc (Filed With SEC on January 9, 2020)

Consulting Agreement, dated January 9, 2020, between Jay Shepard and Aravive, Inc (Filed With SEC on January 9, 2020)

Purchase Agreement, dated November 27, 2019, by and among Aravive, Inc., Piper Jaffray & Co. and Cantor Fitzgerald & Co (Filed With SEC on November 27, 2019)

Equity Distribution Agreement, dated as of March 26, 2019, between Aravive, Inc. and Piper Jaffray & Co (Filed With SEC on March 26, 2019)

Non-Employee Director Compensation Policy, as amended January 3, 2019 (Filed With SEC on March 15, 2019)

Amendment to Jay Shepard Offer Letter dated as of February 28, 2019 (Filed With SEC on March 6, 2019)

First Amendment to 2014 Equity Incentive Plan (Filed With SEC on March 6, 2019)

Amendment to Jay Shepard Offer Letter dated as of February 6, 2019 (Filed With SEC on February 12, 2019)

Offer Letter dated February 1, 2017 and the amendment thereto dated May 30, 2018 by and between Aravive Biologics, Inc. and Vinay Shah (Filed With SEC on February 12, 2019)

Severance Agreement dated May 31, 2018 and amendment thereto dated September 24, 2018 between Aravive Biologics, Inc. and Vinay Shah (Filed With SEC on February 12, 2019)

Offer Letter dated January 1, 2017 by and between Aravive Biologics, Inc. and Gail McIntyre (Filed With SEC on February 12, 2019)

Severance Agreement dated May 31, 2018 and amendment thereto dated September 24, 2018 between Aravive Biologics, Inc. and Gail McIntyre (Filed With SEC on February 12, 2019)

Separation Agreement with Paul Westberg effective November 15, 2018 (Filed With SEC on November 20, 2018)

Separation Agreement with Tracy Woody effective November 15, 2018 (Filed With SEC on November 20, 2018)

Sublease dated August 21, 2018, by and among Versartis, Inc. and Eva Automation, Inc (Filed With SEC on September 20, 2018)

Cancer Research Grant Contract, dated December 1, 2015, by and between the Cancer Prevention and Research Institute of Texas and Ruga Corporation (Filed With SEC on August 3, 2018)

Exclusive License Agreement, dated January 25, 2012, by and between The Board of Trustees of the Leland Stanford Junior University and Ruga Corporation (Filed With SEC on August 3, 2018)

Amendment to the Exclusive License Agreement, dated July 26, 2012, by and between the Board of Trustees of Leland Stanford Junior University and Ruga Corporation (Filed With SEC on August 3, 2018)

Amendment No. 2 to the Exclusive License Agreement, dated June 29, 2015, by and between The Board of Trustees of the Leland Stanford Junior University and Ruga Corporation (Filed With SEC on August 3, 2018)

Amendment No. 3 to the Exclusive License Agreement, dated September 25, 2017, by and between The Board of Trustees of the Leland Stanford Junior University and Ruga Corporation (Filed With SEC on August 3, 2018)

Master Manufacturing Services Agreement, dated July 11, 2016, by and between WuXi Biologics (Hong Kong) Limited and Aravive Biologics, Inc (Filed With SEC on August 3, 2018)

License Agreement, dated December 1, 2017, by and between WuXi Biologics (Hong Kong) Limited and Aravive Biologics, Inc (Filed With SEC on August 3, 2018)

Indemnification Agreement, dated October 17, 2016, by and between Ruga Corporation and Vinay Shah (Filed With SEC on August 3, 2018)

Agreement and Plan of Merger and Reorganization, dated June 3, 2018, by and among Versartis, Inc., Aravive Biologics, Inc. and Velo Merger Sub, Inc (Filed With SEC on June 4, 2018)

Form of Support Agreement, by and between Versartis, Inc. and Aravive Biologics, Inc.s directors, officers and certain stockholders (Filed With SEC on June 4, 2018)

Form of Support Agreement, by and between Aravive Biologics, Inc. and Versartis, Inc.s directors, officers and certain stockholders (Filed With SEC on June 4, 2018)

Offer Letter with Robert Gut, dated August 30, 2017 (Filed With SEC on March 6, 2018)

Reduction in Force Severance Benefit Plan, dated October 4, 2017 (Filed With SEC on March 6, 2018)

Separation Agreement with Joshua T. Brumm, dated November 4, 2017 (Filed With SEC on March 6, 2018)

VERSARTIS, INC. $150,000,000 COMMONSTOCK SALES AGREEMENT (Filed With SEC on August 10, 2017)

Amendment No. 2 (hereinafter the "Amendment No. 2") to the Technology Transfer, Clinical Supply Agreement dated October 23, 2012, (hereinafter the "Agreement") (Filed With SEC on August 7, 2017)

AMUNIX OPERATING INC. 500 Ellis Street Mountain View, CA 94043 (Filed With SEC on August 7, 2017)

Operating Lease Agreement by and between Versartis, Inc. and Bohannon Associates dated March 17, 2017 (Filed With SEC on May 10, 2017)

BI Contract No. 119898 COMMERCIAL SUPPLY AGREEMENT (Filed With SEC on March 10, 2017)

EXCLUSIVE LICENSE AND SUPPLY AGREEMENT by and between VERSARTIS GmbH, VERSARTIS, INC. and TEIJIN LIMITED EXCLUSIVE LICENSE AND SUPPLY AGREEMENT (Filed With SEC on November 4, 2016)

$60,000,500 VERSARTIS,INC. Common Stock, Par Value $0.0001 Per Share UNDERWRITING AGREEMENT (Filed With SEC on September 29, 2016)

Versartis,Inc. Non-Employee Director Compensation Policy Adopted by the Board: March 3, 2014 Amended by the Compensation Committee: May 21, 2015 Amended by the Compensation... (Filed With SEC on May 4, 2016)

Versartis, Inc. 4200 Bohannon Drive, Suite 250 Menlo Park, CA 94025 02/27/2015 (Filed With SEC on May 4, 2016)

Versartis, Inc. 4200 Bohannon Drive, Suite 250 Menlo Park, CA 94025 02/16/2016 (Filed With SEC on May 4, 2016)

Versartis,Inc. Non-Employee Director Compensation Policy Adopted by the Board: March 3, 2014 Amended by the Compensation Committee: May 21, 2015 (Filed With SEC on August 5, 2015)

4200 Bohannon Drive, Suite 250 | Menlo Park, CA 94025 | 650 ###-###-#### (main) (Filed With SEC on August 5, 2015)

Versartis, Inc. 4200 Bohannon Drive, Suite 250 Menlo Park, CA 94025 May 12, 2015 (Filed With SEC on August 5, 2015)

[] Shares VERSARTIS, INC. COMMONSTOCK, PAR VALUE $0.0001 PER SHARE UNDERWRITING AGREEMENT (Filed With SEC on January 20, 2015)

VERSARTIS, INC. RESTRICTED STOCK UNIT GRANT NOTICE (2014 EQUITY INCENTIVE PLAN) (Filed With SEC on April 17, 2014)

TECHNOLOGY TRANSFER AND CLINICAL SUPPLYAGREEMENT (Filed With SEC on March 19, 2014)

Amendment No. 1 (hereinafter the Amendment No. 1) to the Technology Transfer, Clinical Supply Agreement dated October 23, 2012, (hereinafter the Agreement) (Filed With SEC on March 19, 2014)

[] Shares VERSARTIS, INC. COMMONSTOCK, PAR VALUE $0.0001 PER SHARE UNDERWRITING AGREEMENT (Filed With SEC on March 19, 2014)

VERSARTIS, INC. CHANGE IN CONTROL SEVERANCE PLAN (Filed With SEC on March 10, 2014)

VERSARTIS, INC. 2014 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS:MARCH 3, 2014 APPROVED BY THE STOCKHOLDERS:MARCH 5, 2014 IPO DATE/EFFECTIVE DATE:MARCH , 2014 (Filed With SEC on March 6, 2014)

VERSARTIS, INC. 2014 EMPLOYEE STOCK PURCHASE PLAN ADOPTED BY THE BOARD OF DIRECTORS:MARCH 3, 2014 APPROVED BY THE STOCKHOLDERS:MARCH 5, 2014 (Filed With SEC on March 6, 2014)

VERSARTIS, INC. INDEMNIFICATION AGREEMENT (Filed With SEC on March 6, 2014)

AMENDMENT NO. 2 TO SECOND AMENDED AND RESTATED LICENSING AGREEMENT (Filed With SEC on March 6, 2014)

OFFICE LEASE KILROYREALTY MENLO CORPORATE CENTER KILROY REALTY, L.P., a Delaware limited partnership, asLandlord, and VERSARTIS,INC., a Delaware corporation, as Tenant. TABLE OF... (Filed With SEC on March 6, 2014)

WARRANT TO PURCHASE EQUITY SECURITIES OF VERSARTIS, INC. (Voidafter October , 2017) (Filed With SEC on February 18, 2014)

VERSARTIS, INC. FOURTHAMENDED AND RESTATED INVESTORS RIGHTS AGREEMENT February 14, 2014 TABLE OF CONTENTS (Filed With SEC on February 18, 2014)

Office Lease SHOREBREEZE SHOREBREEZEI REDWOOD CITY, CALIFORNIA Between CA-SHOREBREEZELIMITED PARTNERSHIP, a Delaware limited partnership as Landlord, and VERSARTIS, Inc.,... (Filed With SEC on February 18, 2014)

VERSARTIS, INC. 2009 STOCK PLAN ADOPTED ON FEBRUARY 17, 2009 AS AMENDED ON MAY 13, 2009, SEPTEMBER 10,2010, FEBRUARY 14, 2011, JUNE 16, 2011, JANUARY 18,2012, MAY 1, 2012, OCTOBER... (Filed With SEC on February 18, 2014)

VERSARTIS, INC. 2009 STOCK PLAN NOTICE OF STOCK OPTION GRANT (INSTALLMENTVESTING) (Filed With SEC on February 18, 2014)

TECHNOLOGY TRANSFER AND CLINICAL SUPPLYAGREEMENT (Filed With SEC on February 18, 2014)

Amendment No. 1 (hereinafter the Amendment No. 1) to the Technology Transfer, Clinical Supply Agreement dated October 23, 2012, (hereinafter the Agreement) (Filed With SEC on February 18, 2014)

Assignment of Agreement A Technology Transfer and Clinical Supply Agreement dated October 23, 2012 (Contract Number: BI: 63790), including all attachments, amendments and... (Filed With SEC on February 18, 2014)

SERVICES AGREEMENT (Filed With SEC on February 18, 2014)

SECOND AMENDED AND RESTATED LICENSING AGREEMENT (Filed With SEC on February 18, 2014)

VERSARTIS, INC. 500 Ellis Street Mountain View, CA94043 February 3, 2011 (Filed With SEC on February 18, 2014)

AMENDMENT NO. 1 TO SECOND AMENDED AND RESTATED LICENSING AGREEMENT (Filed With SEC on February 18, 2014)

VERSARTIS, INC. December 20, 2010 (Filed With SEC on February 18, 2014)

VERSARTIS, INC. 275 SHORELINE DRIVE, SUITE 450 REDWOOD CITY, CA 94065 November 8, 2013 (Filed With SEC on February 18, 2014)

VERSARTIS, INC. 500 ELLIS STREET MOUNTAIN VIEW, CA 94043 February 10, 2011 (Filed With SEC on February 18, 2014)

Category

Industry

Companies

Contracts

Aravive, Inc. Contracts & Agreements